VEGFA and hepatocellular carcinoma: A previous randomized controlled trial (RCT) of sorafenib versus placebo explored the prognostic value of serum VEGF and its predictive value for the sorafenib benefits in patients with advanced HCC and found that VEGF can independently influence the prognosis of HCC patients but failed to predict the survival benefits from sorafenib [25].